Skip to content

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Clinicopathological and immunohistochemical profiles of early-onset breast cancer in women under 45 years old

Background: Early-onset breast cancer (EOBC), defined as breast cancer in women under 45 years, is often associated with more aggressive biological behavior and poorer prognosis compared to older patients. Objectives: (1) To evaluate the clinicopathological, immunohistochemical characteristics, and molecular subtypes of EOBC; (2) To investigate the associations between selected clinicopathological features and immunohistochemical profiles. Materials and methods: A retrospective cross-sectional study was conducted on 72 patients with invasive breast cancer aged <45 years at Hue University of Medicine and Pharmacy Hospital from January 2023 to December 2025. Results: The majority of tumors were >2 cm, with a high rate of lymph node metastasis (61.1%); most patients presented at stage II (54.2%). Invasive carcinoma of no special type (83.3%) and histological grade II (56.9%) predominated. Hormone receptor positivity was observed in 70.8% (ER) and 69.4% (PR) of cases, while a high Ki-67 index (≥20%) was present in 69.4%. Luminal B was the most common molecular subtype (38.0%). Significant associations were found between tumor size and clinical stage, as well as between histological grade and both hormone receptor status and molecular subtype (p < 0.05). Conclusion: EOBC in this study demonstrates aggressive clinicopathological features and distinct molecular profiles, highlighting the critical role of tumor biology in disease behavior and its potential therapeutic implications. Keywords: early-onset breast cancer, immunohistochemistry, molecular subtype.

Phương Thảo Tiên Nguyễn, T. Trần, Anh Hung Tran et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.